Therapeutic exploitation of checkpoint defects in cancer cells lacking p53 function.

Journal article

Cytotoxic agents form the basis of most cancer therapies. These agents primarily affect rapidly proliferating cells, so their use incurs morbidity associated with damage to tissues such as bone marrow and gastrointestinal mucosa. Clinical outcome would be improved if it were possible to develop therapeutics with more specific activity against p53-deficient cancers, which account for over 50% of all cases. p53 deficiency alters the cellular response to DNA damage in that it leaves cells with a...

Expand abstract

Authors: Dixon, H; Norbury, C

• Journal: Cell cycle (Georgetown, Tex.)
• Volume: 1
• Issue: 6
• Pages: 362-368
• Publication date: 2002-01-01
• DOI: 10.4161/cc.1.6.257
• EISSN: 1551-4005
• ISSN: 1538-4101
• Language: English
• Keywords: Humans; Protein Kinases; Cytotoxins; Antineoplastic Agents; G2 Phase; Animals; Genes, cdc; Neoplasms; DNA Damage; Drug Design; Tumor Suppressor Protein p53; Cell Death